XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Net revenues $ 3,819 $ 3,661
Cost of sales 2,048 2,079
Gross profit 1,771 1,582
Research and development expenses 242 234
Selling and marketing expenses 608 546
General and administrative expenses 278 296
Intangible assets impairments 80 178
Other assets impairments, restructuring and other items [1] 673 110
Legal settlements and loss contingencies 106 233
Other loss (income) 1 (2)
Operating income (loss) [1] (218) (13)
Financial expenses, net 250 260
Income (loss) before income taxes [1] (467) (272)
Income taxes (benefit) (52) (19)
Share in (profits) losses of associated companies, net 4
Net income (loss) (419) (253)
Net income (loss) attributable to non-controlling interests (280) (33)
Net income (loss) attributable to Teva $ (139) $ (220)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ (0.12) $ (0.2)
Diluted $ (0.12) $ (0.2)
Weighted average number of shares (in millions):    
Basic 1,123 1,115
Diluted 1,123 1,115
[1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.